Form 4: Axogen Director Sells Shares After Option Exercise

Axogen Director Kathy Johnson Weiler exercised stock options and sold a total of 46,653 shares of common stock on December 16, 2025.

Summary

• Director Kathy Johnson Weiler exercised 18,248 employee stock options at an exercise price of $7.04 per share on December 16, 2025.
• Director Kathy Johnson Weiler also exercised 21,825 employee stock options at an exercise price of $6.95 per share on December 16, 2025.
• A total of 40,073 shares were acquired through these option exercises.
• Simultaneously, 46,653 shares of common stock were sold in multiple transactions at weighted average prices of $29.547 and $29.55 per share.
• The sales included the 40,073 shares acquired from the option exercises and an additional 6,580 previously held shares.
• Following these transactions, the Director holds 0 shares of common stock directly.
• The Director retains 43,651 unexercised employee stock options with an exercise price of $6.95, which vest in three equal annual installments, with the first vesting date on December 20, 2024.

Sentiment

Score: 4

Explanation: While the director realized significant gains from option exercises, the complete liquidation of direct common stock holdings could be viewed with slight caution by investors, though it's a common practice for directors to diversify or manage tax liabilities.

Positives

• The Director realized a substantial profit from exercising options and selling shares, indicating the stock's appreciation since the options were granted, with sale prices significantly higher than exercise prices.
• The exercise of options demonstrates that the options were in-the-money, reflecting value in the company's stock.

Negatives

• The complete liquidation of direct common stock holdings by a director, even if for personal financial planning or tax management, could be perceived with some caution by investors.

Future Outlook

The filing does not contain forward-looking statements or guidance, as it is a transactional report of insider activity.

Industry Context

This Form 4 filing details an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or competitive analysis.

Stakeholder Impact

• Shareholders: May observe a director reducing direct common stock ownership, which could be interpreted in various ways, from tax planning to a lack of confidence, though it is a common event for insiders managing their equity compensation.

Next Steps

• Future vesting of 43,651 employee stock options on their respective anniversary dates, with the next vesting on December 20, 2024.

Key Dates

Recommendation

The filing reports a director's exercise of stock options and subsequent sale of shares, a common event for insider compensation and tax planning. While the director sold all directly held common stock, they still retain a significant number of unexercised options. This transaction alone does not provide sufficient fundamental information to warrant a 'buy' or 'sell' recommendation, suggesting a 'hold' position until further financial or operational updates are available. The significant profit realized by the director from the option exercise indicates the stock has performed well for option holders.

Keywords

Axogen, AXGN, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Director Transaction, Equity Compensation